New York, June 10, 2026, 08:02 (ET)
- Nuvalent was up 39.28% at $123.25 after GSK said it would acquire the cancer drug maker for $124 a share in cash.
- The shares now move more like a merger-arb play than a high-risk biotech bet. Investors are tracking tender offer schedules, antitrust steps, and FDA calendar dates.
- The FDA is reviewing two Nuvalent lung-cancer drugs, with target dates set for September and November 2026.
Nuvalent is trading on deal odds now, not on drug data. Shares last traded at $123.25, up 39.28%, after GSK said it will buy the Nasdaq-listed biotech for $124 per share in cash. That leaves just a small discount to the offer price. Nuvalent’s stock is being valued more like a GSK takeover play than an oncology bet.
Nuvalent stock got a new cap Tuesday after the company agreed to a buyout. GSK said it will make a tender offer for all outstanding Class A and Class B shares at $124 each, within 10 business days. Tender offers pay cash straight to shareholders and are often used to speed up takeovers. The $124 offer is 40% over Nuvalent’s previous close and 26% above its 30-day volume-weighted average price (VWAP), which tracks average trading prices by volume.
Nuvalent’s 8-K lays out what investors have to do. The deal needs a majority of the company’s Class A shares tendered. It’s subject to U.S. antitrust review under Hart-Scott-Rodino, but there’s no financing condition. Deerfield Management-linked entities, along with some Nuvalent directors and officers, agreed to tender shares accounting for about 28% of the outstanding Class A.
Nuvalent is trading close to the offer price, backed by strong support. The board told shareholders to take the deal. The merger contract sets a $350.475 million breakup fee if Nuvalent picks a better bid or switches its stance in some cases. A higher offer could still happen, but the terms make the GSK deal the likely outcome.
GSK is picking up more than a single drug. The buyout brings in both zidesamtinib and neladalkib, which are late-stage kinase inhibitors. Kinase inhibitors are drugs that block certain enzymes involved in cancer growth. Both candidates go after specific genetic forms of non-small cell lung cancer, the most common lung cancer. Each drug has FDA Breakthrough Therapy and Orphan Drug tags. The FDA action date for zidesamtinib is September 18, 2026. For neladalkib, it’s November 27, 2026.
GSK is also picking up NVL-330, an early-stage HER2 inhibitor for HER2-altered non-small cell lung cancer, as well as Nuvalent’s preclinical pipeline. GSK CEO Luke Miels said the deal brings “immediate new sales growth opportunities” and creates a platform in lung cancer for Ris-Rez, the company’s B7-H3 antibody-drug conjugate, which is in Phase 3. Nuvalent Investors
GSK is watching the clock as closely as the data. The drugmaker said its planned purchase is set to help revenue from 2027, and should lift both core operating profit and core EPS in 2027 and 2029, once synergies and reshuffling are counted in. GSK also flagged that if it wraps up the deal in the third quarter of 2026, it sees low single-digit percentage dilution to core EPS in 2026, 2027 and 2028.
Nuvalent shares have nearly closed the gap to the cash offer, with the price now just $0.75 under the deal. That leaves a spread around 0.6%. Nuvalent’s investor page showed 51.7 million shares had changed hands and the company’s market cap stood at about $9.7 billion. Merger-arb traders piled in right after the news.
Analysts are treating the stock as a takeout play instead of a standalone biotech. MT Newswires on MarketScreener said TD Cowen cut Nuvalent to Hold with a $124 target Wednesday. Guggenheim also downgraded to Neutral and lowered its target to $124 from $151. This isn’t about science—it’s about the cash bid now blocking most of the usual upside.
GSK’s fight for ALK-positive lung cancer market share stays alive even if the Nuvalent deal goes through. Reuters said GSK will have to take on existing drugs like Pfizer’s Lorbrena and Roche’s Alecensa. That competition should have more impact on GSK’s later returns than on Nuvalent’s short-term trading. It also keeps investors focused on how the FDA handles labels, safety warnings, and launch plans.
There are risks that remain. The deal needs enough shareholders to tender, the antitrust waiting period to end, and no legal or regulatory roadblocks. Nuvalent says in its filing that FDA approval might not happen on the expected schedule or at all, and early trial data could turn out to be no guide to final results. More studies could be needed before the FDA signs off. If the deal falls through, the stock probably trades down to a level that reflects its drug risk, not cash value.
The next filings on the radar are GSK’s Schedule TO and Nuvalent’s Schedule 14D-9 statement, both expected to detail how the tender offer will work for shareholders. After those, attention turns to the FDA: zidesamtinib is set for September 18, neladalkib follows on November 27. Those are the two targets that pushed GSK to offer $10.6 billion upfront despite neither drug holding U.S. approval yet.
